ArticleCancer cell international2025
Unlocking the secret of glioblastoma multiforme: the role of lactylation in tumor progression, drug resistance and immune microenvironment.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy.Current oncology reports · 2026Review
- Multi-omics profiling of sodium-overload (NECSO) programs identifies NEK8 as a central driver of colorectal cancer progression through single-cell and spatial transcriptomics.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM), the most prevalent and lethal type of brain cancer, is characterized by a poor prognosis despite advancements in comprehensive treatments, including surgery, chemotherapy, and radiotherapy. Lactylation, an emerging epigenetic modification, has been shown to influence the biological behavior of tumor cells; however, its role in GBM remains to be further elucidated.
methodsIn this study, we analyzed the relationship between lactylation-related genes (LRGs) and malignant biological behavior, temozolomide resistance, and the immune microenvironment of GBM using scRNA-seq data from public databases. Subsequently, we identified temozolomide-resistant lactylation-related genes (TMZR-LRGs) through differential gene expression analysis. Based on these genes, we proceeded to classify GBM subtypes and establish a risk prediction model to assess patient prognosis and treatment response. Finally, we validated the impact of lactylation on TMZ resistance and malignant biological behavior of GBM both in vivo and in vitro by knocking out UBE2E1 to increase cellular lactylation levels.
resultScRNA-seq analysis and in vivo and in vitro experiments both demonstrated that lactylation was significantly up-regulated in GBM cells. In the GBM subtype, MES-like cells have the highest lactylation level. Furthermore, an increase in lactylation levels enhanced the malignant proliferation and temozolomide resistance of GBM cells. The risk model based on TMZR-LRGs effectively predicted the prognosis and immune characteristics of GBM patients and had the potential to accurately identify targeted therapeutic drugs for GBM.
conclusionLactylation is critical for malignant progression, temozolomide resistance and the establishment of an immunosuppressive microenvironment of GBM. The risk model based on lactylation-related genes is an effective tool for assessing the prognosis and treatment response of GBM patients. LRGs have potential as therapeutic targets for GBM, providing a new direction for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.